Oliver Luxxe Assets LLC Purchases 36,280 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Oliver Luxxe Assets LLC increased its stake in Catalyst Pharmaceuticals by 106.6%, acquiring an additional 36,280 shares in the first quarter, raising its total ownership to 70,305 shares valued at approximately $1.7 million.
• Institutional investors own 79.22% of Catalyst Pharmaceuticals, highlighting robust interest from large funds in the biopharmaceutical company.
• Catalyst Pharmaceuticals' stock has recently seen fluctuations in analyst ratings, with some firms upgrading to a "strong-buy" while others have downgraded to a "hold."

Oliver Luxxe Assets LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 106.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 70,305 shares of the biopharmaceutical company's stock after buying an additional 36,280 shares during the period. Oliver Luxxe Assets LLC owned 0.06% of Catalyst Pharmaceuticals worth $1,705,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Algert Global LLC grew its position in shares of Catalyst Pharmaceuticals by 1.0% in the 1st quarter. Algert Global LLC now owns 48,390 shares of the biopharmaceutical company's stock valued at $1,173,000 after acquiring an additional 470 shares during the period. GAMMA Investing LLC lifted its stake in Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 579 shares during the last quarter. Hohimer Wealth Management LLC grew its holdings in Catalyst Pharmaceuticals by 3.6% during the first quarter. Hohimer Wealth Management LLC now owns 18,070 shares of the biopharmaceutical company's stock worth $438,000 after purchasing an additional 629 shares during the period. Vestcor Inc grew its holdings in Catalyst Pharmaceuticals by 3.0% during the first quarter. Vestcor Inc now owns 28,705 shares of the biopharmaceutical company's stock worth $696,000 after purchasing an additional 840 shares during the period. Finally, Illinois Municipal Retirement Fund increased its position in Catalyst Pharmaceuticals by 1.6% during the first quarter. Illinois Municipal Retirement Fund now owns 60,638 shares of the biopharmaceutical company's stock worth $1,470,000 after buying an additional 929 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 1,600 shares of the business's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider directly owned 41,081 shares in the company, valued at $1,085,360.02. The trade was a 3.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 10.40% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Trading Up 2.5%

Catalyst Pharmaceuticals stock opened at $21.08 on Friday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.00 and a 12 month high of $26.58. The stock's 50 day moving average is $21.29 and its 200-day moving average is $22.60. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 0.86 and a beta of 0.70.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Zacks Research cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Finally, Wall Street Zen cut shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $33.20.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.